- Schindler et al. 2021 Yale Phase 2 migraine pilot (n=10): a single dose of 0.143 mg/kg psilocybin reduced migraine days over the following 2 weeks vs placebo.
- Sample is small. Effect was clear but modest. Larger trials in progress.
- The cluster headache evidence is stronger than migraine, despite the conditions sharing some pathophysiology.
- Mechanism: 5-HT receptor activity overlaps with triptan family (5-HT1B/1D), potentially modulating the trigeminovascular system that drives both conditions.
- Standard care (CGRP inhibitors, triptans, propranolol, topiramate) remains first line. Psilocybin is for patients failing standard prevention.
Migraine, in plain terms
Migraine is a primary headache disorder with throbbing unilateral pain, nausea, photophobia, and phonophobia, lasting 4-72 hours per attack. Subtypes: with or without aura. Chronic migraine is defined as 15+ headache days per month for 3+ months.
Migraine affects roughly 12% of adults globally. Genetic component is real. The trigeminovascular system and cortical spreading depression are central to the pathophysiology.
Standard care, briefly
Acute: triptans (sumatriptan, rizatriptan etc.), gepants (rimegepant), ditans (lasmiditan), ergotamines, NSAIDs. Preventive: propranolol, topiramate, valproate, amitriptyline, candesartan, CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) for moderate-to-severe cases. Botox for chronic migraine.
Standard care works for many but not all. Treatment-resistant chronic migraineurs are the population most interested in psilocybin protocols.
Why tryptamines (might) work for migraines
- 5-HT1B/1D shared with triptans. Triptans treat acute migraine by binding 5-HT1B/1D receptors, vasoconstricting cranial vessels and inhibiting trigeminal pain transmission. Psilocybin and LSD have affinity at this same family alongside their primary 5-HT2A activity.
- Trigeminovascular modulation. The same pathway involved in cluster headache resets. Suggestive of a shared “reset” mechanism.
- BOL-148 (non-hallucinogenic LSD analog) data. Karst 2010 showed BOL-148 active in cluster, suggesting the relevant mechanism may not require psychedelic experience. Migraine application speculative but plausible.
- Anti-inflammatory and neuroplasticity effects. Possibly relevant to chronic migraine’s neuroplastic component.
The Schindler trial and follow-up
| Study | Year | Design | Finding |
|---|---|---|---|
| Schindler et al., Yale migraine pilot | 2021 | RCT crossover, n=10 migraine | Single 0.143 mg/kg psilocybin reduced migraine days at 2 weeks vs placebo |
| Schindler et al., cluster Phase 2 | 2022 | RCT, n=14 cluster | 3× psilocybin doses reduced cluster attacks (related condition) |
| Sewell, Halpern, Pope (cluster + migraine survey) | 2006 | Retrospective survey | Self-reports of migraine response to psilocybin/LSD; less robust signal than cluster |
| Yale migraine Phase 2b extension | In progress | RCT, larger sample | Pending |
Migraine vs cluster headache
| Dimension | Migraine | Cluster headache |
|---|---|---|
| Pain character | Throbbing, often unilateral, with nausea/photophobia | Excruciating unilateral periorbital, autonomic features (tearing, ptosis) |
| Duration per attack | 4-72 hours | 15-180 minutes |
| Attack pattern | Episodic or chronic; daily in chronic | Cycles of multiple daily attacks for weeks-months, then remission |
| Psilocybin evidence | 1 small Phase 2 RCT (Schindler 2021) | Larger Phase 2 + decades of patient registry data |
| Effect size in trials | Modest reduction in migraine days | Cluster cycle abortion or substantial reduction |
| Patient community | Smaller microdosing/macrodosing community | Active “cluster-busters” community since 1990s |
Observed protocols
The Yale migraine trial used a single dose of 0.143 mg/kg synthetic psilocybin (~10 mg in a 70 kg adult, mildly hallucinogenic). For cluster headache, the patient-derived “cluster-busters” protocol of 3 sub-hallucinogenic doses spaced 5 days apart is widely used; some migraineurs adopt it.
Microdosing for migraine is anecdotal. No trial. Some users report fewer attacks on a Fadiman protocol, but selection bias and tracking quality are issues.
Triptan washout: Avoid triptans for 5 days before any psilocybin/LSD dose. Same 5-HT1B/1D receptor competition as in cluster protocols.
Do not pursue this if you have:
Bipolar I or family history · Schizophrenia spectrum personal/family · Currently taking lithium, MAOIs, or SSRIs without supervised plan · Recent MI or unstable cardiovascular disease · Pregnancy · Migraine with aura PLUS additional stroke risk factors (the cardiovascular interaction is theoretical but not zero).
Risks specific to migraine patients
- Triggering an attack mid-dose. Acute autonomic shifts can occasionally provoke a migraine. Have rescue triptan available (taken 5 days before, not during).
- Migraine with aura + stroke risk. Migraine with aura modestly elevates stroke risk. Adding cardiovascular load from psilocybin during the dose is theoretical but not nothing.
- CGRP inhibitor interactions. Erenumab, fremanezumab, galcanezumab have no characterized interaction with psilocybin. Conservative reading: do not assume safety.
- Sourcing in flaring patients. Migraine pain impairs decision-making. Plan when not in attack.
Who should not pursue this
- Anyone with active untreated mania, psychosis, or severe cardiovascular disease.
- Anyone hoping to skip first-line preventive trials.
- Anyone unable to source from a known, tested supply.
- Anyone with migraine with aura plus additional stroke risk factors without cardiology clearance.
Integration practices
- Trigger managementHeadache diary, identify patterns. Sleep, hydration, alcohol, hormonal cycles.
- Sleep architectureMigraine and sleep are bidirectional. Fixed wake time, 7+ hours.
- MovementAerobic exercise has preventive evidence. 30 min daily moderate.
- BreathworkDaily coherent breathing reduces autonomic dysregulation. See breathwork resources.
- Magnesium and B2Both have small preventive effect in meta-analyses. Cheap to try.
- TrackingMonthly headache day count is the primary efficacy signal. Without data the question is unanswerable.
When to seek professional help
New severe headache, sudden “thunderclap” headache, headache with neurological deficit, fever, or after head injury: emergency evaluation, not microdosing. American Migraine Foundation: americanmigrainefoundation.org. For crisis: 988 (US).
